Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:1
  • preuzimanja u poslednjih 30 dana:1

Sadržaj

članak: 4 od 32  
Back povratak na rezultate
2017, vol. 74, br. 11, str. 1036-1042
Dodatni uticaj visokih doza alfakalcidola na mišićnu funkciju prilikom lečenja bolesnika sa aktivnom formom reumatoidnog artritisa
aUniverzitet u Beogradu, Medicinski fakultet, Institut za reumatologiju
bKliničko-bolnički centar Zvezdara, Beograd
cUniverzitet u Nišu, Medicinski fakultet

e-adresasimicpasalickatarina@gmail.com
Ključne reči: artritis, reumatoidni; alfakalcidol; mišići; bolest, progresija
Sažetak
Uvod/Cilj. Hormon D (vitamin D) igra važnu ulogu u imunoregulaciji i koštano-mišićnom metabolizmu. Cilj rada bio je ispitivanje uticaja alfakalcidola (1αD3) analoga hormona D, i prednizona, na mišićnu funkciju i aktivnost bolesti kod obolelih od aktivnog reumatoidnog artritisa (RA). Metode. U istraživanje je bilo uključeno 67 bolesnika sa RA koji su imali aktivnu bolest (indeks aktivnosti bolesti - DAS28 > 3,2), uprkos maksimalno podnošljivoj dozi metotreksata (MTX), tokom prethodna tri meseca. Prikupljeni su podaci o aktivnosti bolesti (DAS28), mišićnoj funkciji [(test ustajanja sa stolice (CRT), test ustani i kreni (TUG), šestominutni test hodanja (6MWT), tandem hod (TW)], kao i zapaljenski i bezbednosni laboratorijski nalazi. Bolesnici su nasumično raspoređeni na tromesečno lečenje: 1 μg (grupa A1) 2 μg (grupa A2) ili 3 μg (grupa A3) 1αD3 dnevno ili prednizon (grupa C) 20 mg dnevno, prvih mesec dana, potom 10 mg, uz MTX. Rezultati. Na kraju lečenja u svim terapijskim grupama nađena je visoko statistički značajno snižena aktivnost bolesti (p < 0,01). U grupi A2, lečenih 1αD3 u dozi 2 µg/dan značajno su poboljšani TUG i 6MWT, a kod lečenih 1αD3 3 µg (A3 grupa) došlo je do visoko statistički značajnog poboljšanja CRT (p < 0,01) i značajnog poboljšanja 6MWT (p < 0,05). U grupi C došlo je do visoko statistički značajnog sniženja nivoa vitamina D (25(OH)D3) u serumu (p < 0,01), nasuprot njegovom povećanju kod lečenih alfakalcidolom. Zaključak. Alfakalcidol u dozi 2 µg i 3 µg dnevno podjednako je efikasan kao prednizon (13,3 mg dnevno) u kontroli aktivnosti RA, a ima i dodatni povoljan efekat na mišićnu funkciju.
Reference
Adorini, L. (2002) 1,25-Dihydroxyvitamin D3 analogs as potential therapies in transplantation. Curr Opin Investig Drugs, (10): 1458−63
Aletaha, D., Neogi, T., Silman, A.J., Funovits, J., Felson, D.T. (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis, 69(9); 1580-8
Andjelkovic, Z., Vojinovic, J., Pejnovic, N., Popovic, M., Dujic, A., Mitrovic, D., et al. (1999) Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol, 17(4); 453-6
Arnett, F.C., Edworthy, S.M., Bloch, D.A., Mcshane, D.J., Fries, J.F., Cooper, N.S., Healey, L.A., Kaplan, S.R., Liang, M.H., Luthra, H.S., Medsger, T.A., Mitchell, D.M., Neustadt, D.H., P (1988) The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis & Rheumatism, 31(3): 315-324
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med, 166(1): 111-7
Avina-Zubieta, J.A., Thomas, J., Sadatsafavi, M., Lehman, A.J., Lacaille, D. (2012) Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Annals of the Rheumatic Diseases, 71(9): 1524-1529
Cantorna, M.T., Hayes, C.E., de Luca, H.F. (1998) 25- dihydroxycholecalcipherol inhibits progression of arthritis in murine models of human arthritis. J Nutr, 128(1); 68-72
Carlberg, C., Molnar, F. (2012) Current Status of Vitamin D Signaling and Its Therapeutic Applications. Current Topics in Medicinal Chemistry, 12(6): 528-547
Cunningham, J., Zehnder, D. (2011) New Vitamin D analogs and changing therapeutic paradigms. Kidney International, 79(7): 702-707
Cutolo, M., Otsa, K., Uprus, M., Paolino, S., Seriolo, B. (2007) Vitamin D in rheumatoid arthritis. Autoimmunity Reviews, 7(1): 59-64
Deluca, H. F. (2001) Vitamin D: its role and uses in immunology. FASEB Journal, 15(14): 2579-2585
Deluca, H.F. (2004) Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr, 80(6 Suppl); 1689S-96S
Dukas, L.C., Schacht, E. (2005) Low creatinine clearance, glucocorticoid treatment, rheumatoid arthritis - different etiologies for low D-hormone syndrome and its associated increased risk for falls. J Rheumatol Suppl, 76: 44-6
Dukas, L., Bischoff, H.A., Lindpaintner, L.S., Schacht, E., Birkner-binder, D., Damm, T.N., Thalmann, B., Stähelin, H.B. (2004) Alfacalcidol Reduces the Number of Fallers in a Community-Dwelling Elderly Population with a Minimum Calcium Intake of More Than 500 Mg Daily. Journal of the American Geriatrics Society, 52(2): 230-236
Eduardo-Canosa, S., Fraga, R., Sigüeiro, R., Marco, M., Rochel, N., Moras, D., Mouriño, A. (2010) Design and synthesis of active vitamin D analogs. Journal of Steroid Biochemistry and Molecular Biology, 121(1-2): 7-12
Ekdahl, C., Borman, G. (2001) Muscle strength, endurance and aerobic capacity in rheumatoid arthritis: A comparative study with healthy subjects. Ann Rheum Dis, 51(1): 35-40
Etten, E.van, Mathieu, C. (2005) Immunoregulation by 1,25-dihydroxyvitamin D3: Basic concepts. Journal of Steroid Biochemistry and Molecular Biology, 97(1-2): 93-101
Ferrucci, L., Penninx, B.W., Levill, S.G., Corti, M.C., Pahor, M., Wallace, R., i dr. (2000) Characteristics of non-disabled older persons who perform poorly in objective tests of lower extremity function. J Am Geriatr Soc, 48(9): 1102-10
Fransen, J., van Riel, P.L.C.M. (2009) The Disease Activity Score and the EULAR Response Criteria. Rheumatic Disease Clinics of North America, 35(4): 745-757
Gaal, J., Lakos, G., Szodoray, P., Kiss, J., Horvath, I., Horkay, E., et al. (2009) Immunologicaland clinical Effects of Alfacalcidol in Patients with Psoriatic Arthropathy: Results of an Open Follow up Pilot Study. Acta Derm Venereol, 89(2); 140-4
Hein, G., Oelzner, P. (2000) Vitamin D metabolites in rheumatoid arthritis: Results - Hypotheses - Consequences. Zeitschrift für Rheumatologie, 59(S1): I28-I32
Kanis, J.A., Oden, A., Johnell, O., Johansson, H., de Laet, C., Brown, J., et al. (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int, 18(8); 1033-46
Lau, K.H., Baylink, D.J. (2001) Treatment of 1,25 (OH)2D3(D- hormone) deficiency/resistance with D-hormone and analogs. Osteologie, 10(25): 28−39
Lips, P., Binkley, N., Pfeifer, M., Recker, R., Samanta, S., Cohn, D. A., Chandler, J., Rosenberg, E., Papanicolaou, D. A. (2010) Once-weekly dose of 8400 IU vitamin D3 compared with placebo: effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency. American Journal of Clinical Nutrition, 91(4): 985-991
Lips, P. (1996) Vitamin D Supplementation and Fracture Incidence in Elderly Persons. Annals of Internal Medicine, 124(4): 400
Lipsky, P.E. (2005) Rheumatoid arthritis. u: Kasper D.; Fauci A.; Braunwald E.; Hauser S.; Lango D.; Jameson J. [ur.] Harrison's Principles of Internal Medicine, New York, NY, USA: McGraw-Hill, 16th ed. p. 1968-77
Merlino, L.A., Curtis, J., Mikuls, T.R., Cerhan, J.R., Criswell, L.A., Saag, K.G. (2004) Vitamin D intake is inversely associated with rheumatoid arthritis: Results from the Iowa Women's Health Study. Arthritis & Rheumatism, 50(1): 72-77
Nagpal, S., Na, S., Rathnachalam, R. (2005) Noncalcemic Actions of Vitamin D Receptor Ligands. Endocrine Reviews, 26(5): 662-687
Nordin, B. E. C., Need, A. G., Morris, H. A., Horowitz, M. (1999) The Special Role of ``Hormonal'' Forms of Vitamin D in the Treatment of Osteoporosis. Calcified Tissue International, 65(4): 307-310
Norman, A.W. (2006) Vitamin D Receptor: New Assignments for an Already Busy Receptor. Endocrinology, 147(12): 5542-5548
Oelzner, P., Müller, A., Deschner, F., Hüller, M., Abendroth, K., Hein, G., Stein, G. (1998) Relationship Between Disease Activity and Serum Levels of Vitamin D Metabolites and PTH in Rheumatoid Arthritis. Calcified Tissue International, 62(3): 193-198
Orimo, H. (1994) Clinical Application of 1α(OH)D 3 in Japan. Aktuelle Rheumatologie, 19(S 1): 27-30
Podsiadlo, D., Richardson, S. (1991) The timed up & go: A test of basic functional mobility for frail elderly persons. J Am Geriatr Soc, 39(2): 142-8
Pollard, L., Choy, E.H., Scott, D.L. (2005) The consequences of rheumatoid arthritis: Quality of life in the individual patient. Clin Exp Rheumatol, 23(5 Suppl 39): S43-52
Rejnmark, L. (2011) Effects of vitamin D on muscle function and performance: a review of evidence from randomized controlled trials. Therapeutic Advances in Chronic Disease, 2(1): 25-37
Richy, F., Schacht, E., Bruyere, O., Ethgen, O., Gourlay, M., Reginster, J.-Y. (2005) Vitamin D Analogs Versus Native Vitamin D in Preventing Bone Loss and Osteoporosis-Related Fractures: A Comparative Meta-analysis. Calcified Tissue International, 76(3): 176-186
Richy, F., Ethgen, O., Bruyere, O., Reginster, J. (2004) Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporosis International, 15(4): 301-310
Ringe, JohannD., Schacht, E. (2004) Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol. Rheumatology International, 24(4):
Rocha, O.M.da, Batista, A.de A.P., Maestá, N., Burini, R.C., Laurindo, I.M.M. (2009) Sarcopenia da caquexia reumatoide: conceituação, mecanismos, consequências clínicas e tratamentos possíveis. Revista Brasileira de Reumatologia, 49(3): 288-301
Roubenoff, R. (2009) Rheumatoid cachexia: a complication of rheumatoid arthritis moves into the 21st century. Arthritis Research & Therapy, 11(2): 108
Schacht, E., Richy, F. (2008) Reductions of falls in elderly. The central role of alfacalcidol in a multi-dimensional paradigm. Internet J Epidemiol, 7(1); 9
Schacht, E., Ringe, J. D., Dorst, A., Rahlfs, V. W., Faber, H. (2004) Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatology International, 24(2): 63-70
Scharla, S., Schacht, E., Bawey, S., Kamilli, I., Holle, D., Lempert, U.G. (2003) Pleiotropic effects of alfacalcidol in elderly patients with rheumatoid arthritis. Arthritis Rheum, 23(3); 268-74
Shumway-Cook, A., Brauer, S., Woolacott, M. (2000) Predicting the probability for falls in community dwelling older adults using timed up and go test. Phys Ther, 80(9); 896-903
Smolen, J.S. (2012) Treat-to-target: Rationale and strategies. Clin Exp Rheumatol, 30(4 Suppl 73): S2-6
Smolen, J.S., Landewé, R., Breedveld, F.C., Buch, M., Burmester, G., Dougados, M., et al. (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis, 73(3); 492-509
Sørensen, O. H., Lund, BI., Saltin, B., Lund, BJ., Andersen, R. B., Hjorth, L., Melsen, F., Mosekilde, L. (1979) Myopathy in Bone Loss of Ageing: Improvement by Treatment with 1α-hydroxycholecalciferol and Calcium. Clinical Science, 56(2): 157-161
van der Goes, M. C., Jacobs, J. W. G., Boers, M., Andrews, T., Blom-Bakkers, M. A. M., Buttgereit, F., Caeyers, N., Cutolo, M., Da, S.J. A. P., Guillevin, L., Kirwan, J. R., Rovensky, J., Severijns, G., Webber, S., Westhovens, R., Bijlsma, J. W. J. (2010) Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Annals of the Rheumatic Diseases, 69(11): 1913-1919
Visser, M., Deeg, D.J. H., Lips, P. (2003) Low Vitamin D and High Parathyroid Hormone Levels as Determinants of Loss of Muscle Strength and Muscle Mass (Sarcopenia): The Longitudinal Aging Study Amsterdam. Journal of Clinical Endocrinology & Metabolism, 88(12): 5766-5772
Vojinovic, J., Zivanovic-Radnic, T., Simic-Pasalic, K., Sefik-Bukilica, M., Damjanov, N. (2012) Alfacalcidol (D hormone analog) modulate inflammatory cytokine production without conversion to calcitriol. Ann Rheum Dis, 71(Suppl 3): 672
Wolfe, F., Michaud, K. (2010) The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Arthritis Research & Therapy, 12(2): R35
Yamauchi, Y., Tsunematsu, T., Konda, S., Hoshino, T., Itokawa, Y., Hoshizaki, H. (1989) A double blind trial of alfacalcidol on patients with rheumatoid arthritis (RA). Ryumachi, 29(1): 11−24. (Japanese)
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.2298/VSP160227300S
objavljen u SCIndeksu: 16.11.2017.
metod recenzije: dvostruko anoniman
Creative Commons License 4.0

Povezani članci

J Med Biochemistry (2013)
Vitamin D za dobro zdravlje
Holick Michael F.

J Med Biochemistry (2020)
Vitamin D i nivoi tiol-disulfidne homeostaze kod žena u postmenopauzi sa sindromom preaktivne bešike
Ustundag Yasemin, i dr.

Praxis medica (2019)
Analiza vrednosti vitamina D u serumu u akutnom virusnom bronhiolitisu
Vujnović-Živković Zorica, i dr.

prikaži sve [7]